Analytical Data
-
基因名
CD80
- Application
-
别名
CD80；CD28LG；CD28LG1；LAB7；T-lymphocyte activation antigen CD80
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P33681
-
表达区间
35-242aa
-
氨基酸序列
VIHVTKEVKEVATLSCGHNVSVEELAQTRIYWQKEKKMVLTMMSGDMNIW PEYKNRTIFDITNNLSIVILALRPSDEGTYECVVLKYEKDAFKREHLAEV TLSVKADFPTPSISDFEIPT SNIRRIICSTSGGFPEPHLSWLENGEEL NAINTTVSQDPETELYAVSSKLDFNMTTNHSF MCLIKYGHLRVNQTFN WNTTKQEHFPDN
-
分子量
50 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Recombinant Human CD79B Protein，His
Cat：PA1000-533DB
Recombinant Human PRSS50 Protein，His
Cat：PA1000-9252
Protein Description
CD80, also known as B7-1, is a co-stimulatory molecule primarily expressed on the surface of antigen-presenting cells (APCs). It plays a critical role in the activation of T cells by binding to its receptor CD28 on T cells, facilitating immune responses. Understanding the role of CD80 is essential in various immunological contexts, including vaccine development, cancer immunotherapy, and autoimmune diseases. Recombinant CD80 proteins have been generated to study their functional properties, interactions with various ligands, and potential applications in therapies. The use of CD80 in recombinant forms allows researchers to explore its structural characteristics, enhance T cell activation in vitro, and implement it in experimental models. This can lead to innovative approaches in modulating immune responses, paving the way for novel treatments in immunotherapy and other therapeutic interventions. Thus, the study of CD80 recombinant proteins not only sheds light on fundamental immune processes but also provides a foundation for therapeutic advancements in managing diseases driven by immune dysregulation.
